Investors may face disappointment as Shenzhen Hepalink's lim...
Investors may face disappointment as Shenzhen Hepalink's limited growth clashes with its high P/S ratio. Analysts require a positive shift in future revenue forecasts to justify the current valuation.
Unpleasant Surprises Could Be In Store For Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Shares
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment